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Classical major histocompatibility complex (MHC) class I and II molecules present peptides to cognate T-cell receptors on the
surface of T lymphocytes. The speciﬁcity with which T cells recognize peptide-MHC (pMHC) complexes has allowed for the
utilization of recombinant, multimeric pMHC ligands for the study of minute antigen-speciﬁc T-cell populations. In type 1
diabetes (T1D), CD8+ cytotoxic T lymphocytes, in conjunction with CD4+ T helper cells, destroy the insulin-producing β cells
within the pancreatic islets of Langerhans. Due to the importance of T cells in the progression of T1D, the ability to monitor and
therapeutically target diabetogenic clonotypes of T cells provides a critical tool that could result in the amelioration of the disease.
By administering pMHC multimers coupled to ﬂuorophores, nanoparticles, or toxic moieties, researchers have demonstrated the
ability to enumerate, track, and delete diabetogenic T-cell clonotypes that are, at least in part, responsible for insulitis; some
studies even delay or prevent diabetes onset in the murine model of T1D. This paper will provide a brief overview of pMHC
multimer usage in deﬁning the role T-cell subsets play in T1D etiology and the therapeutic potential of pMHC for antigen-speciﬁc
identiﬁcation and modulation of diabetogenic T cells.
1.Introduction
Due to antigen-speciﬁc assaults on the insulin producing
beta (β) cells of the pancreas by diabetogenic T cells, insulin
synthesis and secretion is lost, resulting in dysregulation of
blood glucose homeostasis and aberrant lipid and protein
metabolism in type 1 diabetic (T1D) patients. T1D is
one of the most prevalent chronic autoimmune diseases
in the United States and aﬀects ∼36 million individuals
worldwide [1, 2]. The incidence of T1D is predicted to
increase worldwide by 3% annually [3]. With administration
ofexogenoussourcesofinsulinviadailyinjections,continual
pump therapy, or islet replacement transplants, diabetics can
currently enjoy near normal life spans and reduced incidence
of heart disease, kidney failure, blindness, and neuropathy
[4]. However, none of the currently available therapies can
adequately quell the long-term risks of hypoglycemia or
microvasculardamageandtheﬁnancialexpenseoftreatment
[1, 4]. In addition, the total direct and indirect costs
associated with diabetes in 2007 were $174 billion dollars in
the United States [1]. Therefore, new therapies are needed
to reduce the burden of this chronic disease on both the
individual and society.
The aforementioned T1D therapies are directed only at
the consequences of the disease rather than the causative
agent(s). While the ultimate cause of T1D is not currently
deﬁned and is likely multifactorial [5], T cells speciﬁc for
islet antigens are the proximate cause of β cell destruction.
Diabetogenic T cells that have been inappropriately activated
and allowed to escape central and peripheral tolerance
mechanisms (possibly due to assistance from aberrant innate
cells [6]) have been implicated in β cell damage in both the
nonobese diabetic (NOD) mouse and the human form of
disease. In peripheral lymphoid organs and in circulation,
CD4+ T cells and CD8+ T cells interact with peptide-
majorhistocompatibility complexclassIIorclassI(pMHCII
or pMHCI) molecules, respectively. MHCII molecules are2 Clinical and Developmental Immunology
externally displayed on the cell surface of professional anti-
gen presenting cells (APCs) and contain peptide fragments
primarily derived from extracellular proteins, while classical
MHCI molecules are found on the surface of all nucleated
cells and present peptides of cytosolic origin. In T1D,
diabetogenicCD4+Tcells(TH)areresponsibleforproviding
the cytokine microenvironment in which islet-speciﬁc CD8+
T cells (CTL) destroy β cells. Furthermore, islet-speciﬁc TH
activity may also be cytotoxic to islets at later disease stages,
and CTL may not need prior costimulation before killing
β cells [7–11]. Thus, both TH and CTL are contributors to
diabetes pathogenesis and are suitable targets for strategies
aimed at preventing T1D. However, it is currently unknown
whether T1D preventative strategies will be more eﬀective
when targeting CTL or TH, and future therapies will likely
target both subsets of autoreactive T cells.
TheabilitytomodulatethebehaviorofTcellsistherefore
an approach for novel treatments in T1D and other T-
cell-mediated diseases (e.g., multiple sclerosis, transplant
rejection). Most T-cell-targeting strategies have utilized non-
speciﬁc or blanket therapies, such as Thymoglobulin or anti-
CD3monoclonalantibodies,thattargetallTcells.Therefore,
these treatments may also prevent protective immunity by
the adaptive immune system, resulting in susceptibility to
new infections, viral reactivation, or increased risk of cancer
[12, 13]. Thus, researchers have pursued various means of
exclusively modulating the autoreactive T cells with antigen,
which can be delivered covalently linked to tolerizing
cells, within viral vectors, or as whole proteins or soluble
peptide fragments [14, 15]. Many studies have addressed
the identity of cognate antigens for diabetogenic T cells in
mouse and human T1D [16], but the relative importance
of each peptide is still unknown for human disease [17].
While the repertoire of diabetogenic T-cell epitopes has
been investigated extensively, the molecular form of antigen
(e.g., whole protein versus peptide fragments), the route of
delivery,ormodiﬁcationssuchascarrierproteinsoradjuvant
combinations still need to be more clearly deﬁned in order to
produce eﬃcient therapeutic strategies [15, 18].
One major obstacle to the use of soluble peptides to
target antigen-speciﬁc T cells is the relatively short half-
life of these molecules once administered. To remedy this,
researchers have designed vehicles that mimic the natural
setting in which a peptide is presented to T cells; that is,
peptides are combined in vitro with puriﬁed or recombinant
MHC molecules to create soluble, stable complexes [19, 20].
These peptide-MHC (pMHC) complexes are then able to
bind to cognate TCR on antigen-speciﬁc T cells. The binding
aﬃnity of the TCR to a single pMHC molecule is in the
weak micromolar range but can be increased by producing
pMHC multimers. The multimeric form allows for numer-
ous pMHC-TCR interactions to occur simultaneously on
the surface of a cognate T cell to synergistically increase
the binding avidity into the nanomolar range [21]. This
advancementhasallowedforidentiﬁcationandenumeration
of T-cell populations that are found at frequencies of less
than 10−5. The most common form of pMHC multimer
currently used is the tetramer, which is produced by linking
four biotinylated pMHC complexes via streptavidin. In
most forms, pMHC multimers can be labeled for use in
ﬂow cytometry, magnetic resonance imaging, or modulation
of antigen-speciﬁc T-cell activity. This paper will cover
how pMHC multimers have been used to unravel T1D
pathogenesis and how these agents may be applied to treat
the disease.
2. Peptide-Major Histocompatibility Complex
Multimers in T1D
Our understanding of islet-speciﬁc T cells in the patho-
genesis of T1D has been greatly enhanced following the
elucidation of major β cell autoantigens and the creation
of pMHC multimers speciﬁc for diabetogenic T-cell subsets.
In fact, the use of these tools may allow for more accurate
prognoses than the currently used predictions based on
islet autoantibody titers. For example, researchers can collect
blood samples from at-risk individuals and evaluate TH and
CTL speciﬁc for islet antigens using ﬂuorochrome-labeled
pMHCtetramers.WhileearlierstudiesofautoreactiveTcells
inperipheralcirculationrequiredexvivopeptidestimulation
in order to detect antigen-speciﬁc TH cells via multimer-
labeling [28, 29], advances in pMHCII technology have
allowed for direct detection of diabetogenic T cells in lymph
nodes of NOD mice [30], indicating that pMHC technology
may eventually allow for enumeration of autoreactive TH
clonotypes in peripheral circulation. Alternatively, the use of
ELISPOTtechniques,whilestillrequiringastimulatoryincu-
bation period, also allows for enumeration of islet-reactive T
cells in diabetics [31] though the diﬀerences between pMHC
multimer and ELISPOT assays in detecting islet-speciﬁc T
cells that physiologically function as diabetogenic clonotypes
remain to be clariﬁed [32]. Utilizing pMHCI multimers to
label the blood cells of young NOD mice, elevated numbers
of CTL speciﬁc for the NRP mimotope, a synthetic analog of
theisletantigenIGRP206−214,werefoundtostronglycorrelate
with the degree of insulitis [33]. Importantly, this correlation
predicted the onset of overt diabetes prior to detection of
hyperglycemia. In a similar fashion, investigators detected
pMHCI-speciﬁc autoreactive CTL in the blood of recent-
onset diabetics that were not present in control subjects
[34]. The presence of islet-reactive CTL in peripheral blood
also correlated with impending insulin dependence in islet
transplant recipients. Thus, pMHC multimers oﬀer clinically
relevant tools for T1D that may surpass current diagnostic
protocols.
In addition to the value of pMHC multimers as
diagnostic tools for blood specimens, this technology has
led to demonstrations of the presence and expansion of
diabetogenic T cells within secondary and tertiary immune
compartments. Liu et al. were the ﬁrst to describe the
presence of glutamic acid decarboxylase (GAD)65-reactive
TH cells in the lymphoid tissues of NOD mice by uti-
lizing tetramers composed of murine MHCII molecules
that were complexed with GAD65-derived peptides [28].
Similar protocols and results were described in recent-onset
human T1D patients [29]. Wong et al. utilized pMHCI
tetramers loaded with an insulin-derived peptide epitopeClinical and Developmental Immunology 3
(determined via cDNA screening libraries) to demonstrate
CTL inﬁltration into islets of young NOD mice, ﬁnding that
insulin B15−23-reactive CTL comprised a large proportion of
islet inﬁltrating T cells and that this population decreased
over time [35]. Studies by Amrani et al. indicated that NRP-
A7-speciﬁc CTLs predominate as animals age [36] and that
this phenomenon occurs due to a process deemed “avidity
maturation,” in which higher-avidity, more aggressive IGRP-
reactive CTL clonotypes expand within the islets over time,
likely due to a lack of tolerance mechanisms that restrict the
clones as disease progresses [37].
Such insights could indicate that there is a primary
clonotype responsible for T1D initiation—but which one?
Krishnamurthy et al. demonstrated that NOD mice tolerized
to proinsulin do not develop IGRP-speciﬁc CTL inﬁltration
into islets and, importantly, do not become diabetic, while
those tolerized to IGRP still developed proinsulin-reactive
CTL, resulting in T1D [38]. These results support the idea
of a driver clonotype (proinsulin-reactive) and the recruit-
ment of secondary eﬀectors (IGRP-reactive) through the
phenomenonof“epitopespreading.”Thus,itmaybediﬃcult
to determine which speciﬁcity to target with antigen-speciﬁc
therapy, particularly in light of the variability of diabetogenic
CTL populations found in both mice and humans. For
example, Lieberman et al. compared CTL speciﬁcities in
age-matched NOD mouse islets at diﬀerent time points and
found diﬀerent antigen-speciﬁc clonotypes predominating
in each animal [39]. Similarly, research involving recent-
onset human diabetics also found no immunodominant
CTLreactivityacrossindividuals[40].Again,suchvariability
could arise from epitope spreading; alternatively, these
data could signify that there is no universal, underlying
epitope responsible for T1D induction in either species.
Even this worst case scenario—where private T-cell speci-
ﬁcitiesinitiatediabetogenesis—doesnotautomaticallydoom
antigen-speciﬁc-based treatment as a practical therapy for
T1D, because of immunodominance, which likely restricts
these speciﬁcities to one or a few epitopes per MHC
haplotype. Thus, a limited number of antigen-speciﬁc
agents presumably would cover a large percentage of the
diabetic patient population. This restriction is reinforced
by the relative dominance of some class I (HLA-A∗0201,
B∗3906, or C∗0501) and class II (DPA1∗0103-DPB1∗0202
or DRB1∗0405-DQA1∗0301-DQB1∗0302) alleles in T1D
[41].
Whether there is a primum movens diabetogenic T-
cell speciﬁcity is debatable; however, T-cell traﬃcking to
the islets clearly occurs prior to overt diabetes. Tetramers
labeled with magnetic nanoparticles have allowed real-time
magneticresonanceimagingofNRP-speciﬁcCTLinﬁltrating
NOD islets [42, 43]. Such a noninvasive procedure could be
invaluable for the detection of insulitis in at-risk patients,
further supporting the use of multimerized pMHC as
diagnostic measurements of T1D onset.
In addition to the use of pMHC multimers described
previously, these constructs can also be employed to manip-
ulate both TH and CTL subsets in vivo. The strategy of
pMHC therapy in T1D is based on TCR-pMHC binding
in the absence of costimulatory or cytokine signals, thereby
inducing anergic or regulatory T-cell phenotypes. Numerous
studies have described the possible outcomes, such as full
priming, partial activation, unresponsiveness, or induction
of apoptosis, following administration of pMHCI to CTL
in vitro and in vivo [10, 44–46]. Similar results have been
detected in human TH treated with pMHCII multimers
[47, 48]. Such varying eﬀects of pMHC administration upon
modulation of diabetogenic T cells will be highlighted later,
but are likely due to pMHC multimer avidity, functional
plasticity of the clonotype targeted, and the molecule
conjugated to the pMHC multimer. Speciﬁcally, shortened
linkagelengthbetweenthepMHCImonomersinmultimeric
complex correlated with induction of CTL apoptosis [44],
and the numbers, or valence, of pMHCII monomers in
complex was determined to aﬀect TH fate [26]. Alternatively,
if the goal is to delete speciﬁc T-cell subsets, pMHC
multimers may be used to deliver toxic moieties to cognate
T cells [49–52].
Advantages of pMHC multimer therapies over “blanket”
or mAb-based treatments include the capacity to rapidly
create “designer” pMHC multimers that directly target dia-
betogenic T cells. Speciﬁcally, pMHCI folding protocols can
incorporate photocleavable peptides into the MHCI binding
groove that can be rapidly replaced by peptides of interest
following exposure to UV light, while still maintaining the
MHCI complex [53]. This technique was recently applied
to human T1D patients and led to the discovery of new
preproinsulin epitopes against which T-cell frequencies were
found to correlate with islet transplant rejection outcomes
[54]. Unlike in toxic mAb therapies, diabetogenic T cells
cannot be selected to escape targeting by toxic multimers
because the pMHC is the ligand for the TCR, which is
necessary for recognizing and killing β cells. However,
certain issues will need to be addressed before pMHC
become clinically acceptable treatments for T-cell-mediated
diseases. Firstly, multimer therapy in its current form may
be immunogenic, resulting in antimultimer antibodies pro-
duction following repeated administration. Secondly, some
studies have indicated that pMHC therapy may actually
activate T cells and exacerbate disease due to the transfer
of peptides from multimers to native MHC on host tissues
[55]. Yet, the ﬁrst concern could be addressed by altering
the structural design of the therapeutic pMHC to reduce
immunogenicity, while covalent linkage of peptides to the
multimer could obviate the second issue [46]. Lastly, pMHC
administration may induce refractory periods during which
T cells are transiently resistant to binding pMHC complexes
[56]. This issue could be addressed by determining the
optimaldosingintervalinordertoavoiddeliveryduringsuch
periods. While unanticipated technical problems are likely to
arise, the ability to manipulate T cells in an antigen-speciﬁc
manner warrants further investigation into pMHC therapy
for T1D. Table 1 summarizes the designs and outcomes for
pMHC-based experiments targeting autoreactive CTL and
TH cells in diabetes models.
2.1. CD4+ T-Cell-Directed Multimer Usage: pMHCII.
As mentioned previously, TH cells, along with innate
immune cells, are responsible for creating an inﬂammatory4 Clinical and Developmental Immunology
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microenvironment within islets undergoing insulitis. This
cytokine milieu usually includes IL-2, IFN-γ,T N F - α,a n d
IL-12, which promote cellular immune responses and
inﬂammation and may inhibit IL-4 and IL-10 production.
O n eg o a lo fp M H C I Im u l t i m e r - b a s e di m m u n o m o d u l a t i o n
therapy is to shift the TH-cell-mediated inﬂammatory state
to one of a regulatory phenotype [57]. In a double transgenic
T1D mouse model expressing inﬂuenza hemagglutinin
(HA) under the rat insulin promoter, and in which CD4+
T cells are speciﬁc for the HA antigen, Casares et al.
demonstrated the ability of pMHCII dimers to prevent
T1D onset in prediabetic mice and to restore euglycemia
in newly diabetic mice [24]. While untreated mice usually
become diabetic within 10 weeks of age, frequent dimer
treatment induced T regulatory cells that produced IL-10
within the pancreatic islets and also induced anergy of
antigen-speciﬁc TH cells in the spleen, resulting in extended
durations of normoglycemia. In an adoptive transfer model
of T1D, BDC2.5 TH cells (speciﬁc for chromogranin A29−24
[58]) are capable of inducing T1D onset in T-cell deﬁcient
NOD recipients [25]. However, when recipients were treated
with pMHCII dimers that target the BDC2.5 T cells, T1D
was prevented due to the conversion of BDC2.5 TH into
regulatory-type cytokine producers. Speciﬁcally, this eﬀect
was attributable to IL-10, as shown by diabetes progression
in mice treated with antibodies that block IL-10 receptors.
However, the utility of pMHCII dimer treatment was not
translatable to wild-type (WT) NOD mice that contain
TH−cells speciﬁc for numerous other islet antigens. Yet, more
recent work with prediabetic WT NOD mice has conﬁrmed
previous studies in that pMHCII dimers do indeed induce
T-cell phenotype conversion and can eﬀectively block
progression to overt diabetes if TH speciﬁc for GAD65-
derived epitopes are targeted [27], possibly indicating that
responses to this antigen occur prior to those directed at the
chromogranin A epitope.
A second aim of pMHCII multimer therapy is the
antigen-speciﬁc deletion of autoreactive TH cells. Such ther-
apies attempt to prevent T1D pathogenesis by eliminating
TH populations, thus preventing the development of an
inﬂammatory microenvironment and/or the full activation
of islet-speciﬁc CTL. The ﬁrst eﬀorts at clonal deletion of
antigen-speciﬁc TH cells utilized toxic moieties, doxorubicin
or mycophenolate, conjugated to pMHCII multimers [49,
50]. However, studies that expand on these initial ﬁndings in
T1D have not been reported. In another work, Preda-Pais et
al.utilized thedouble transgenicHAmousemodel described
previously and determined the eﬀect of increasing the num-
bers of pMHCII monomers in multimeric complexes (thus
increasing avidity for cognate TCRs) [26]. Clonal deletion
of antigen-speciﬁc TH cells was achieved using octameric
pMHCII complexes, which resulted in prolonged protection
fromT1D,ascomparedtotreatmentwiththepMHCIIdimer
previouslyusedbythesamegroup. Furtherstudiesregarding
the eﬃcacy of pMHCII multimers in preventing T1D via
clonal TH cell ablation in WT NOD mice have not yet been
described. Thus, pMHCII-based therapies show promise in
their capacity to delay or prevent overt T1D in susceptible
mice via induction of anergic or regulatory phenotypes and
by deletion of diabetogenic TH cells.
2.2. CD8+ T-Cell-Directed Multimer Usage: pMHCI.
Immunomodulation of CTL activity via pMHCI multimers
was ﬁrst described by Dal Porto et al., who created dimeric
MHCI-Ig fusion proteins that were capable of inhibiting
alloreactive CTL in vitro [21]. Subsequently, other studies
conﬁrmedthatpMHCImultimerscaninhibitCTLactivityin
vivo [59, 60]. The mechanisms by which pMHCI multimers
modulate aggressive activity of CTL were addressed in a
murine model of tissue rejection by Maile et al. [45]. This
study utilized the male HY alloantigen to determine the
capacity of pMHCI multimer treatment to prevent tissue
rejection in vivo. Administration of pMHCI to na¨ ıve female
recipients of male skin grafts induced a CD8lo phenotype
in allospeciﬁc CTL, which corresponded to antigen
hyporesponsiveness and the production of TGFβ.T h u s ,
pMHCI tetramer treatment induced immunosuppressive
CTL in female mice that prevented other alloreactive
CTL from rejecting male tissue grafts. Results of these
studies indicate that immunomodulation of diabetogenic
CTL clonotypes might also be feasible. However, when
pMHCI multimers targeting IGRP-reactive CTL for
immunomodulation were administered to NOD mice,
diabetes was not prevented (unpublished observations).
More recently, promising results for pMHCI multimers
have been obtained in both WT and humanized (trans-
genic HLA-A∗0201 expression) NOD mice [22]. Tsai et al.
utilized iron-oxide nanoparticles coated with antigenic islet
epitope-displaying MHCI molecules to determine the eﬀects
on diabetogenic CTL. Surprisingly, pMHCI-nanoparticle
treatment boosted numbers of the antigen-speciﬁc CTL
clonotype, but prevented or reversed diabetes in pre- and
newly-diabetic NOD mice. This ﬁnding was attributed to
the expansion of low avidity, autoregulatory (or suppres-
sor) CTL that are capable of suppressing autoimmunity
via IFNγ-, indoleamine-2, 3-dioxygenase-, and perforin-
dependent mechanisms in a non-antigen-speciﬁc manner.
Thus, pMHCI-based therapies may prevent and even coun-
teract insulitis in T1D-susceptible individuals via enhance-
ment of autoregulatory mechanisms.
While pMHCI-mediated expansion of islet-speciﬁc sup-
pressor CTL appears to hold great promise for recent-
onset T1D treatment, it is plausible that such therapies
would be ineﬀective for modulating all islet-speciﬁc CTL,
such as memory-like CTL clonotypes found in long-term
diabetics. Therefore, the use of pMHCI multimers to specif-
ically ablate diabetogenic clonotypes may be advantageous
for islet transplantation, since islet antigen-speciﬁc CTL
clonotypes mediate recurrence of T1D [61–65]. The ﬁrst
description of a toxic pMHCI multimer was published
by Yuan et al. [51] and utilized tetramers conjugated to
a radionuclide, which eliminated antigen-speciﬁc CTL in
vitro. Using saporin as a toxic agent, we demonstrated
the ablation of transgenic CD8+ T cells in an antigen-
speciﬁc manner in vitro and in vivo [66]. Our group then
demonstratedthattoxicpMHCIadministrationkilledIGRP-
reactive CTL transferred into T-cell deﬁcient NOD.scid6 Clinical and Developmental Immunology
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Figure 1: Schematic representation of the eﬀects of toxic pMHCI tetramer administration to NOD mice. Clockwise from upper left: toxic
moieties, such as saporin, can be linked to pMHCI multimers that are speciﬁc for diabetogenic CTL before being delivered to prediabetic
NOD mice. Toxic pMHCI tetramers can access inﬂamed islets where cognate CTLs are present. Insulitis involves numerous autoreactive
immune cell subsets that act in concert to potentiate diabetogenic CTL and destroy β cells. However, pMHCI multimers can deliver saporin
to diabetogenic CTL clonotypes and induce apoptosis in an antigen-speciﬁc manner. Cognate TCR interacting with saporin-conjugated
pMHCI results in uptake of the tetramer into the lysosome of the CTL. In the lysosome, the toxic pMHCI tetramer is disassociated, allowing
the freed saporin molecules to escape these organelles. Saporin is a potent ribosome-inactivating toxin that can perform multiple rounds of
ribosome disabling, ultimately leading to apoptosis of the CTL and therein preventing further β cell damage by the targeted diabetogenic
clonotype.
recipients [23]. Toxic tetramer treatment also resulted in
the rapid reduction of cognate CTL (>75% eliminated 72
hours post treatment) from the spleens of lymphoreplete
NOD recipients. Furthermore, toxic tetramer-treated WT
NOD mice showed delayed onset of T1D (3 of 10 treated
animals were euglycemic at study completion, compared to
none among the PBS-injected mice), and lasting depletion
(for44weeksaftertreatment)ofcognateCTLfromtheislets.
Lastly, treatment was initiated at 8 weeks of age, a time point
when the autoimmune response is well underway in NOD
mice, indicating that this strategy may be applicable to the
preventionofdiseaseprogression.Figure 1depictsparenteralClinical and Developmental Immunology 7
administration of pMHCI tetramers, conjugated to the
ribosome-inactivating molecule saporin, which can diﬀuse
into pancreatic tissues and interact with diabetogenic CTL
at the site of inﬂammation. Binding of toxin-linked pMHCI
to the cognate TCR results in the uptake of the multimer
into the lysosomes of the T cell, where the toxin is then
cleaved from the tetramer. Released saporin escapes into the
cytosol, inactivating ribosomes and thereby killing the CTL,
whichpreventsβcelldestruction.Thus,immunomodulation
and ablation strategies utilizing pMHCI multimers may be
suitable for preventing progression or recurrence of T1D.
3. Conclusions
In summary, the goals of pMHC multimer usage in T1D
are to create a better prognostic indicator for diabetes
onset or impending islet transplant rejection; to halt the
destructive activity of diabetogenic T-cell clones via anergy
induction, phenotype conversion, or clonal deletion; and
ultimately, to restore the balance of islet-speciﬁc eﬀector
and suppressor T cells in at-risk individuals. Future studies
should address the following issues with pMHC multimer
administration: determining optimal time point of therapy
application (is there an ideal time to deplete antigen-speciﬁc
CTL?) utilizing numerous pMHCI multimers of diﬀerent
speciﬁcities simultaneously (can we modulate multiple CTL
populations?) combining therapies that target CD4+ and
CD8+Tcells(wouldtargetingTH andCTLhaveasynergistic
eﬀect?); combining therapies that target other cell types (will
B cell-depleting antibodies prevent epitope spreading?) and
producing next generation recombinant pMHC molecules
(can we more eﬀectively target islet-reactive T cells?).
Therefore, we believe that this technology will continue to
evolve and perhaps be used in conjunction with existing
therapies to treat or prevent T cell-mediated autoimmune
disorders such as T1D.
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